MannKind Corporation (NASDAQ: MNKD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.14 | Insider Own | 4.19% | Shs Outstand | 319.39M | Perf Week | -5.60% |
| Market Cap | 1.13B | Forward P/E | 149.05 | EPS next Y | 0.02 | Insider Trans | -1.26% | Shs Float | 303.10M | Perf Month | -19.36% |
| Enterprise Value | 1.35B | PEG | - | EPS next Q | -0.08 | Inst Own | - | Short Float | 8.76% | Perf Quarter | -10.15% |
| Income | -44.00M | P/S | 2.88 | EPS this Y | -29.46% | Inst Trans | - | Short Ratio | 5.74 | Perf Half Y | 40.48% |
| Sales | 393.00M | P/B | - | EPS next Y | 113.10% | ROA | -5.96% | Short Interest | 26.55M | Perf YTD | -37.57% |
| Book/sh | -0.21 | P/C | 10.19 | EPS next 5Y | - | ROE | 78.60% | 52W High | 6.51 -45.62% | Perf Year | -34.32% |
| Cash/sh | 0.35 | P/FCF | - | EPS past 3/5Y | - | ROIC | 1.18% | 52W Low | 2.23 58.74% | Perf 3Y | -17.67% |
| Dividend Est. | - | EV/EBITDA | 44.95 | Sales past 3/5Y | 51.68% 39.95% | Gross Margin | 75.69% | Volatility | 3.73% 4.02% | Perf 5Y | -24.68% |
| Dividend TTM | - | EV/Sales | 3.43 | EPS Y/Y TTM | -244.03% | Oper. Margin | 1.97% | ATR (14) | 0.18 | Perf 10Y | -2.20% |
| Dividend Ex-Date | - | Quick Ratio | 1.41 | Sales Y/Y TTM | 37.41% | Profit Margin | -11.08% | RSI (14) | 36.40 | Recom | 2.85 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.72 | EPS Q/Q | - | SMA20 | -9.40% | Beta | 1.09 | Target Price | 9.00 |
| Payout | 0.00% | Debt/Eq | 1.63 | Sales Q/Q | 41.56% | SMA50 | -10.43% | Rel Volume | 1.29 | Prev Close | 3.58 |
| Employees | 592 | LT Debt/Eq | -8.31 | Earnings | Nov 04 | SMA200 | -13.49% | Avg Volume | 4.26M | Price | 3.54 |
| IPO Date | Jul 28, 2004 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -700.00% 1.20% | Net Debt/EBITDA | 9.04 | Volume | 5,511,804 | Change | -1.12% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-06-26 | Reiterated | Wells Fargo | Overweight | $14 → $13 |
| Jul-30-26 | Reiterated | Wells Fargo | Overweight | $11 → $14 |
| Jun-01-26 | Reiterated | Wells Fargo | Overweight | $10 → $11 |
| May-07-26 | Reiterated | HC Wainwright & Co. | Buy | $11 → $10 |
| May-07-26 | Reiterated | Wells Fargo | Overweight | $10 |
| May-07-26 | Reiterated | Mizuho | Outperform | $8.00 → $7.00 |
| Apr-13-26 | Reiterated | Mizuho | Outperform | $8.00 |
| Apr-08-26 | Reiterated | Truist Financial | $7.00 → $6.00 | |
| Feb-27-26 | Downgrade | RBC Capital | Outperform → Sector Perform | |
| Nov-24-25 | Initiated | Truist | Buy | $9.00 |
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 393 | 349 | 286 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 96 | 61 | 77 | — | — | — | — | — | — | |
| Gross Profit | 298 | 288 | 209 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 199 | 144 | 94 | — | — | — | — | — | — | |
| Research and Development | 77 | 66 | 46 | — | — | — | — | — | — | |
| Other Operating Expense | 14 | 39 | -4 | — | — | — | — | — | — | |
| Operating Income | 8 | 39 | 73 | — | — | — | — | — | — | |
| Interest Expense | 44 | 14 | 38 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -12 | -24 | -4 | — | — | — | — | — | — | |
| Net Income Before Taxes | -48 | 1 | 31 | — | — | — | — | — | — | |
| Income Taxes | -5 | -4 | 3 | — | — | — | — | — | — | |
| Consolidated Net Income | -44 | 6 | 28 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -44 | 6 | 28 | — | — | — | — | — | — | |
| Net Income | -44 | 6 | 28 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.14 | 0.02 | 0.10 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.14 | 0.02 | 0.10 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.14 | 0.02 | 0.10 | — | — | — | — | — | — | |
| EBITDA | 30 | 28 | 77 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 283.50 | 66.15 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.78 | 4.97 | 6.16 | — | — | — | — | — | — | |
| Gross Margin | 75.83 | 82.52 | 73.08 | — | — | — | — | — | — | |
| Operating Margin | 2.04 | 11.17 | 25.52 | — | — | — | — | — | — | |
| Net Margin | -11.20 | 1.72 | 9.79 | — | — | — | — | — | — | |
| Shares Outstanding | 309 | 306 | 274 | — | — | — | — | — | — | |
| Market Capitalization | 1,094 | 1,735 | 1,762 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Binder Steven B. | Director | Sep 10 '26 | Sale | 3.81 | 33,558 | 127,856 | 752,309 | Sep 14 |
| Binder Steven B. | Director | Aug 07 '26 | Sale | 4.06 | 39,051 | 158,547 | 785,867 | Aug 10 |
| Thomson David | EVP Genl Counsel & Secretary | Jul 17 '26 | Sale | 4.05 | 24,109 | 97,641 | 797,554 | Jul 17 |
| Binder Steven B. | Director | Jul 17 '26 | Sale | 4.06 | 52,485 | 213,089 | 824,918 | Jul 17 |
| Castagna Michael | Chief Executive Officer | Jul 15 '26 | Option Exercise | 0.00 | 350,260 | 0 | 2,796,979 | Jul 17 |
| Singh Sanjay R | EVP Technical Operations | Jul 15 '26 | Option Exercise | 0.00 | 70,550 | 0 | 525,761 | Jul 17 |
| Thomson David | EVP Genl Counsel & Secretary | Jul 15 '26 | Option Exercise | 0.00 | 93,790 | 0 | 920,089 | Jul 17 |
| Binder Steven B. | Director | Jul 15 '26 | Option Exercise | 0.00 | 93,790 | 0 | 901,798 | Jul 17 |
| Tross Stuart A | Chief People & Workpl Officer | Jul 15 '26 | Option Exercise | 0.00 | 93,790 | 0 | 1,123,950 | Jul 17 |
| Binder Steven B. | Director | May 12 '26 | Sale | 3.29 | 16,940 | 55,733 | 808,008 | May 13 |
| Thomson David | EVP Genl Counsel & Secretary | May 12 '26 | Sale | 3.29 | 3,033 | 9,979 | 826,299 | May 13 |
| Castagna Michael | Chief Executive Officer | Mar 10 '26 | Buy | 2.59 | 100,000 | 259,000 | 2,575,911 | Mar 10 |
| Tross Stuart A | Chief People & Workpl Officer | Jan 08 '26 | Sale | 6.33 | 47,006 | 297,548 | 985,007 | Jan 09 |
| Castagna Michael | Chief Executive Officer | Dec 17 '25 | Option Exercise | 4.55 | 115,804 | 526,908 | 2,570,596 | Dec 19 |
| Castagna Michael | Chief Executive Officer | Dec 17 '25 | Sale | 6.01 | 65,804 | 395,482 | 2,504,792 | Dec 19 |